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Abstract
Background: India and many other high-burden countries have committed to providing universal access to high-
quality diagnosis and drug susceptibility testing (DST) for tuberculosis (TB), but the most cost-effective approach to
achieve this goal remains uncertain. Centralized testing at district-level hub facilities with a supporting sample
transport network can generate economies of scale, but decentralization to the peripheral level may provide faster
diagnosis and reduce losses to follow-up (LTFU).
Methods: We generated functions to evaluate the costs of centralized and decentralized molecular testing for
tuberculosis with Xpert MTB/RIF (Xpert), a WHO-endorsed test which can be performed at centralized and
decentralized levels. We merged the cost estimates with an agent-based simulation of TB transmission in a
hypothetical representative region in India to assess the impact and cost-effectiveness of each strategy.
Results: Compared against centralized Xpert testing, decentralization was most favorable when testing volume at
decentralized facilities and pre-treatment LTFU were high, and specimen transport network was exclusively
established for TB. Assuming equal quality of centralized and decentralized testing, decentralization was cost-saving,
saving a median $338,000 (interquartile simulation range [IQR] − $222,000; $889,000) per 20 million people over
10 years, in the most cost-favorable scenario. In the most cost-unfavorable scenario, decentralized testing would
cost a median $3161 [IQR $2412; $4731] per disability-adjusted life year averted relative to centralized testing.
Conclusions: Decentralization of Xpert testing is likely to be cost-saving or cost-effective in most settings to which
these simulation results might generalize. More decentralized testing is more cost-effective in settings with
moderate-to-high peripheral testing volumes, high existing clinical LTFU, inability to share specimen transport costs
with other disease entities, and ability to ensure high-quality peripheral Xpert testing. Decision-makers should assess
these factors when deciding whether to decentralize molecular testing for tuberculosis.
Keywords: Tuberculosis, Diagnostic techniques and procedures, Cost-benefit analysis, Systems analysis
Introduction
Tuberculosis (TB) is one of the world’s most important
infectious causes of morbidity and mortality, with an
estimated 25% of the world’s population infected [1] and
1.6 million deaths reported in 2017 [2]. Global TB
incidence is declining slowly (2% per year), far short of the
progress needed to achieve global targets [2]. With only
64% of an estimated 10 million new cases reported in
2017 [2], strategies to optimize existing technologies and
interventions to address gaps in TB case detection and
linkage to care are desperately needed.
Xpert MTB/RIF (Xpert), a cartridge-based nucleic acid
amplification test (CBNAAT) for TB with substantially
improved sensitivity relative to sputum smear micros-
copy (SSM) [3], has been recommended by the World
Health Organization (WHO) [4] and scaled up in many
settings worldwide. Many studies have suggested that
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Xpert is both feasible and cost-effective [5–7] in ideal-
ized settings. Nevertheless, in India—as in many re-
source-limited settings—the use of Xpert has largely
been limited to the public sector (at district level or
higher [8]) and often restricted to high-priority popula-
tions including HIV-positive individuals, children, and
people at high risk for multidrug-resistant (MDR) TB
[9]. As a result, in more peripheral settings where the
majority of public-sector patients present for care (e.g.,
primary care clinics), TB diagnosis continues to rely on
SSM and non-microbiological tests.
Since the initial development of the GeneXpert system,
much progress has been made in the development of
smaller point-of-care (POC) instruments. In 2018, the bat-
tery-operated, single-module GeneXpert Edge system was
introduced, and the point-of-care GeneXpert Omni sys-
tem is expected to be released in 2020. As such,
decentralization of Xpert at peripheral facilities using
these POC platforms may help address the problem of
pre-treatment loss to follow-up (LTFU), which is esti-
mated to occur among 13% of individuals with confirmed
TB in Asia [10]. An alternative to decentralization is to
centralize Xpert testing at district-level or reference facil-
ities and establish a “hub-and-spoke” transport network
for clinical specimens (e.g., sputum) [11]. This approach
could enable cost sharing across disease entities, consoli-
date maintenance of high-level infrastructure in more
centralized facilities, and ensure higher testing volume to
achieve economies of scale. South Africa, for example, has
successfully used this centralized model via their National
Health Laboratory Service (NHLS) [12].
Given the resource constraints and the complexity and
heterogeneity of most healthcare systems, it is important
to estimate the impact and cost-effectiveness of more
centralized Xpert testing versus decentralizing Xpert
testing capacity to more peripheral settings. This is also
a question of generalizable importance, as many other
tests on the WHO Essential Diagnostics List (e.g., HIV
viral load testing, glycated hemoglobin measurement for
diabetes) could be performed either centrally or in
point-of-care fashion [13]. To help illustrate the primary
considerations in evaluating the cost and cost-effectiveness
of more decentralized versus more centralized Xpert test-
ing, we constructed a suite of economic and epidemio-
logical models in a hypothetical setting representative of
the Indian public sector.
Methods
Experimental framework
Our primary comparison was between more centralized
Xpert testing for TB at district/city-level hubs with
supporting sample transport networks (“centralized”
scenario) and decentralization of Xpert testing to more
peripheral settings in clinics where microscopy currently
is performed (“decentralized” scenario) within India’s
current public sector system, namely the Revised
National Tuberculosis Control Program (RNTCP) [14].
In the decentralized scenario, we assumed that Xpert is
made available (for example, using battery-operated
Edge instruments, or Omni, in the near future) at the
Microscopy Center (MC), a primary health center serv-
ing approximately 100,000 people with a capacity to per-
form SSM. In this scenario, we assumed a sufficient
number of instruments installed to ensure the same-day
diagnosis of > 90% of all patients with presumptive TB.
In the centralized scenario, we assumed that Xpert is
available only at the District TB Center (DTC), a central
referral facility currently equipped with four-module
GeneXpert IV instruments that cannot readily be imple-
mented at the point of care. There are more than 13,000
MCs in India, with a median of 13 MCs (interquartile
range (IQR) = 9–23) associated per DTC. We assumed
that sputum specimens are transported from individual
MCs to the DTC using a specimen referral network. In
both decentralized and centralized scenarios, we con-
sider only patients who present to peripheral centers
(i.e., MCs) for testing, as decentralization will not affect
outcomes of patients presenting directly to district-level
centers (i.e., DTCs) for diagnosis. In both scenarios, we
assumed that 13% of individuals presenting to care
would experience LTFU prior to treatment initiation and
experience no benefit from TB testing (Fig. 1, red
arrow). These individuals may undergo other diagnostic
encounters, but the cost and outcome of those encoun-
ters are assumed not to differ between scenarios (and
thus not explicitly considered) [10]. Since referral tests
generally cannot provide same-day results, we assumed
that centralized testing would result in additional pre-
treatment LTFU for some patients who would receive
same-day treatment in the decentralized scenario (Fig. 1,
blue arrow); we assume that these patients will return
for follow-up visits and obtain an appropriate (though
delayed) diagnosis in the future. In both strategies, Xpert
was assumed to be used as the primary diagnostic tool
for all presumptive TB patients, a key objective of India’s
2025 National Strategic Plan to ensure universal and up-
front access to molecular diagnostics for TB.
To evaluate cost-effectiveness, our a priori assumption
was that decentralized testing would be more expensive
(as it would require more equipment modules), but also
more effective (as it would reduce pre-treatment LTFU).
To evaluate this trade-off, we first constructed a range
of cost functions to estimate the unit cost of Xpert from
the health system perspective, under various scenarios.
We then adapted a published agent-based simulation of
drug-susceptible (DS) and drug-resistant (DR) TB
transmission in India [15] to estimate the incremental
epidemiological impact and cost-effectiveness (assessed
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as the cost per disability-adjusted life year [DALY]
averted) of decentralized versus centralized Xpert.
Cost model
Using a bottom-up micro-costing method incorporating
data from our previous work in India [5, 16], we
constructed a reference per-test cost table for Xpert (see
Additional file 1: Section S1.2). We estimated the price
of a peripheral single-module GeneXpert unit as
US$2895, with similar per-module maintenance pricing
as the GeneXpert IV [17]. We inflated all Xpert-related
(equipment and cartridge) unit prices by 20% to account
for procurement and installation. We assumed that the
amount of time required to perform an Xpert test did
not differ with centralized versus decentralized testing,
as the procedures are standardized, require minimal
hands-on time, do not differ based on the type of
GeneXpert system used, and can be operated by existing
laboratory staff (e.g., microscopy technicians who cur-
rently perform smear testing at MCs). We also assumed
the equivalent quality of testing, as decentralized testing
is unlikely to be accepted in settings where quality is
substantially compromised. We therefore incorporated
costs of continuous quality control measures under each
strategy.
Anticipating that laboratory workload (number of tests
per day) would strongly influence the unit cost of Xpert
[5, 18], we simulated a range of daily testing volumes for
MCs and DTCs assuming a Poisson distribution of tests
per day and 250 annual operational days. Mean per-test
cost was assessed for each volume scenario based on
annual total cost and testing volume (see Additional file 1:
Section S1.3).
For decentralized testing, we evaluated 15 different
scenarios (Fig. 2) with mean daily testing volumes be-
tween 0.1 (i.e., 25 samples tested per year) and ten (2500
samples/year). This range covers the expected mean
daily workload of 3–6 tests per MC nationwide [14]. For
centralized testing, a total of seven mean daily testing
volume scenarios between 10 (2475 samples/year) and
70+ (17,411 samples/year) were assessed, including costs
associated with sample transport (see Additional file 1:
Section S1.4). At the time of analysis, no published
evidence on costs of establishing or operating sample
transport networks for sputum specimens was available,
to our knowledge. Therefore, we estimated mean per-
sample transport costs based on the following: (a) distri-
butions of MC-to-DTC ratio and mean distance from
MCs to DTC (based on total service area of DTC/num-
ber of MC in the area) in India (see Additional file 1:
Figure S2), (b) hypothetical estimates of the number
of specimens transported, and (c) a range of cost
sharing of sample transport (5 to 100%) with other
clinical specimens (Additional file 1: Table S4). This
Fig. 1 Schematic representation of the tuberculosis (TB) diagnostic process in the public sector. Upon accessing the public sector for TB
diagnosis, individuals are assumed to undergo an initial evaluation that includes Xpert MTB/RIF (or sputum smear microscopy prior to Xpert
implementation). A proportion of those encounters will result in successful diagnosis followed by successful treatment (green arrow) or pre-
treatment loss to follow-up (LTFU) estimated at 13% for both centralized and decentralized scenarios (red arrow). These individuals may undergo
other diagnostic encounters, but those encounters do not result in TB diagnosis, and the cost of those encounters is not considered by the
model. In addition to these individuals, another proportion of individuals (also estimated at 13% in the base case) are expected to experience
pre-treatment LTFU due to diagnostic delays in the centralized scenario (blue arrow). These individuals can return for a future visit in which Xpert
is again performed and TB treatment is successfully initiated. The assumption that all incremental LTFU is followed by a second encounter is
conservative and may underestimate the impact of Xpert in the decentralized scenario. Finally, individuals receiving TB treatment who fail to
recover will undergo a separate encounter after treatment completion in which Xpert is performed and used to guide second-line therapy
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cost was calculated separately for each DTC test
volume scenario (Additional file 1: Table S6).
Costs for clinical encounters (outpatient visits, clinical
evaluation, antibiotic treatment, etc.), TB-specific treat-
ment, and chest X-ray were estimated from sources
including the Global Drug Facility, the MSH Inter-
national Price Tracker, the World Health Organization’s
CHOosing Interventions that are Cost-Effective (WHO-
CHOICE) database [19], and published literature
(Table 1) [22, 23]. Full details of the costing approach
are described in Additional file 1: Section S1.
Agent-based simulation model
We developed an agent-based simulation model of TB
transmission and treatment in India, incorporating
household structure, patients’ care-seeking pathways,
and the public-sector TB care cascade (Fig. 1,
Additional file 1: Figures S4 and S5). A detailed descrip-
tion of the model is presented in Additional file 1:
Section S2 and earlier publications [15, 20, 21, 24].
Briefly, the simulation model was calibrated to 2017
WHO estimates of TB incidence, prevalence, and
mortality in India using a stepwise procedure (see
Additional file 1: Section S2.5). At the end of the calibra-
tion period, we modeled the introduction of Xpert in
area(s) where Xpert testing is not available, as a first-line
test replacing on-site SSM, under decentralized and
centralized testing scenarios as described above. The
model was then run for 10 years to project correspond-
ing changes in the incidence and mortality of DS- and
DR-TB. The core model simulates a population of one
million people, representative of an average-sized district
in India that might contain a single DTC [25]. For each
Xpert testing scenario (centralized versus decentralized),
we generated 2000 independent simulations of TB trans-
mission at the district level. To assess the policy imple-
mentations at a city or state level, we then constructed
larger simulated populations of 20 million people by
combining 20 randomly sampled districts (with replace-
ment) from the original pool of simulations. We
repeated this procedure to achieve a sample of 2000 lar-
ger-scale simulations with a population of 20 million in-
dividuals each. All outcomes were reported as median
values with interquartile uncertainty ranges across these
2000 larger-scale simulated populations.
Cost-effectiveness analysis
Given our a priori assumption that decentralized testing
would be implemented with equal quality and would re-
duce pre-treatment LTFU with no adverse consequences
(i.e., that decentralized testing would be more effective
than centralized testing and thus preferred in settings
where decentralized testing was less costly), we focused
our cost-effectiveness analyses on our tested scenarios
where the unit cost of decentralized testing would be
higher than that of decentralized testing. We selected
Fig. 2 Unit cost of decentralized Xpert testing. Bars show the estimated unit cost (in 2015 US dollars) of decentralized Xpert testing as a function
of the mean daily number of tests performed (x-axis), with the annual test volume shown in parenthesis under each scenario and the cost per
test shown above each bar. Blue bars indicate two representative scenarios chosen for the cost-effectiveness analysis. Costs were derived by
assuming a Poisson distribution of daily test volume and number of single-module Xpert devices sufficient to ensure same-day testing for 90% of
all patients. Above mean daily volumes of approximately one test per day, the unit cost remains relatively stable (between $15 and $20 per
test)—reflecting the fact that, even though a single-module device can perform four tests per day, testing capacity must be maintained at
approximately four times the actual volume in order to assure same-day diagnosis at the 90% level. At less than one test per day, excess (wasted)
testing capacity grows, resulting in substantially increased unit costs at very low testing volumes
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these scenarios based on their conceptual importance:
one scenario of very low decentralized test volumes (0.3
tests per day, as might be seen in more sparsely popu-
lated districts, or as TB incidence declines) and one of
average test volumes (three per day, reflective of mean
MC volumes in India) [14]. We compared these decen-
tralized scenarios against centralized testing at high
volume (> 70 tests per day) with either low or high levels
of shared transport costs (see Fig. 3).
All analyses were performed from the health system
perspective and assessed in 2015 US dollars. The pri-
mary outcome was calculated as the ratio of incremental
costs per disability-adjusted life year (DALY) averted
over a 10-year period, with costs and DALYs discounted
at 3% annually. We benchmarked cost-effectiveness
against a range of cost-effectiveness thresholds (CET)
from $500 to $2000 to reflect more realistic local
constraints than reflected in traditional per capita Gross
Domestic Product (GDP)-based thresholds [26, 27].
Sensitivity analyses
We performed univariate sensitivity analyses for selected
epidemiological and cost-related parameters across the
ranges shown in Table 1. For each analysis, we evaluated
the relative epidemiological impact (reduction in DS-TB
incidence), difference in cost, and incremental cost-ef-
fectiveness, comparing decentralized to centralized
testing. For these analyses, we assumed a decentralized
scenario with moderate volume of three tests per day
and a centralized scenario with no cost sharing for sam-
ple transport. We conducted other sensitivity analyses in
which we separately varied incremental pre-treatment
LTFU in the centralized scenario, diagnostic accuracy of
Xpert, and other drivers of the unit cost per Xpert test
(e.g., estimated useful life).
Results
The unit cost of decentralized Xpert ranged from
$17.20 to $60.81 (Fig. 2), but consistently approxi-
mated $20 per test when MCs performed at least one
test a day (with small fluctuations reflecting the num-
ber of testing modules required). The unit cost of
centralized Xpert depended on the degree to which
the costs of sample transport could be shared with
clinical specimens for non-TB disease entities (e.g.,
from $14.00 to $18.96 in the highest-volume scenario
in Additional file 1: Table S8).
The per-test cost difference between centralized and
decentralized testing was driven primarily by three
factors: centralized (DTC) testing volume, cross-disease
cost sharing of specimen transport under centralized
testing (between 5 and 100% of the sample transport
network dedicated for TB/sputum specimens), and
peripheral (MC) testing volume. At higher decentralized
Table 1 Selected model parameters for post-calibration sensitivity analysis
Parameters Base value Low bound† High bound Reference
Xpert diagnostic accuracy
Sensitivity—smear positive 0.98 0.93 1.00 [3]
Sensitivity—smear negative 0.67 0.60 0.85
Sensitivity—RIF resistance 0.95 0.90 0.97
Specificity—diagnosis of TB disease 0.99 0.98 1.00
Specificity—RIF resistance 0.98 0.97 1.00
Treatment and linkage to care
Probability of empiric treatment at initial encounter 0.25 0.00 0.50 Assumption
Probability of loss to follow-up after initial encounter 0.13 0.05 0.25 [10]
Monthly rate of returning for follow-up encounter 0.46 0.30 0.70 [20]
Probability of treatment failure for drug-resistant TB 0.17 0.10 0.25 WHO 2016
Probability of referring from private provider to public sector 0.67 0.54 0.80 [21]
Type of costs
Cost of initial encounter $12.11 $9.08 $15.14 Recalculated based on [19, 22, 23]
Cost of follow-up encounter $9.53 $7.15 $11.91
Cost of encounter to assess failing treatment $7.39 $5.54 $9.24
Other visits (informal/private) $2.32 $2.06 $2.60
DS-TB treatment, per 6-month course $345.65 $259.24 $432.06
DR-TB treatment, per course $3399.22 $2549.41 $4249.02
†One-way sensitivity analysis was performed by varying each parameter in this table individually between its low and high bounds. For a list of all parameters and
references, see Section S2.6 of Additional file 1
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testing volume (mean daily testing volume of 3 or more
at MCs, represented by λ = 3), differences in costs of be-
tween centralized and decentralized testing (Fig. 3) were
generally small or favored decentralized testing (as indi-
cated by a negative cost estimate). At lower decentra-
lized testing volumes (MC mean daily testing volume of
less than 1 test, for example, λ = 0.3), centralized testing
was generally cheaper than decentralized testing. In both
cases, higher sample transport cost sharing and testing
volumes for centralized testing lowered the unit cost of
centralized testing. Additional description of the calcula-
tion of unit costs and sensitivity analyses around the
drivers of these costs are shown in Additional file 1:
Section S1.6.
Epidemiological impact of decentralized and centralized
Xpert
Assuming that centralized Xpert was used to replace
SSM starting in 2018 (with 13% pre-treatment LTFU
relative to decentralized testing [10]), our model pro-
jected a median TB incidence of 213 [IQR 212–214]
cases per 100,000 in 2028 in a hypothetical region repre-
sentative of India’s public sector where Xpert testing was
previously unavailable. Alternatively, if Xpert was imple-
mented in decentralized fashion (with equal quality and
no pre-treatment LTFU) in the same region, the result-
ing DS-TB incidence in 2028 was projected to be 1.0%
[IQR 0.5–1.6%] lower than with centralized testing,
equivalent to averting a total of 15 [IQR 4–27] new DS-
TB cases per 100,000 population over 10 years (Fig. 4a).
For DR-TB incidence and TB mortality, the difference
between the two strategies was small, with decentralized
testing averting an estimated 1 [IQR − 1 to 5] incident
DR-TB case and 4 [IQR 0–9] total TB deaths per 100,
000 over 10 years (Fig. 4b, c).
Incremental cost-effectiveness of decentralized versus
centralized Xpert
Primary cost-effectiveness results are given in Table 2
and Fig. 5. In the primary analysis, decentralized Xpert
averted an estimated 1.25% [IQR 0.88%, 1.54%] of all
TB-related DALYs, relative to centralized Xpert. Under
the most unfavorable scenario for decentralized testing
(low decentralized volume at 0.3 tests per day and 95%
cost sharing for specimen transport in the centralized
scenario), this gain came at an estimated cost of $3161
[IQR $2412; $4731] per DALY averted. Under the most
favorable scenario (high decentralized volume at 3 tests
per day and no cost sharing), decentralized testing was
cost saving compared to centralized testing, saving a
Fig. 3 Difference in unit cost of more centralized versus more decentralized Xpert testing for tuberculosis (TB). Shown on the y-axis is the range
of difference in mean per-test cost of Xpert test (inclusive of equipment, consumables, sample transport, human resources, and overheads)
performed in the centralized scenario (district-level testing with sample transport network, assuming a range between 5 (“high cost sharing”) and
100% (“exclusive TB sample transport”) of this network—represented by the size of each bar—is used for sputum specimens/TB testing) and in
the decentralized scenario (testing at the microscopy center level). Values above the horizontal line ($0, gray dotted line) denote that
decentralized testing is more expensive than centralized testing, whereas values below that line denote that centralized testing is more costly.
The dumbbell dot plot on the left represents a setting where a mean of 0.3 tests are performed per day at the peripheral level (i.e., smaller, low-
volume clinics), whereas those on the right represent a mean volume of 3 tests per day. The seven boxes in each series represent, from left to
right, increasing mean test volume of 10 to 70 or more tests per day at the centralized testing facility. Such variation might be seen, for example,
if an increasing number of peripheral clinics referred specimens to the same district center, or if the district center performed testing for other
purposes (e.g., inpatients, drug susceptibility testing). In general, increasing testing volume makes maximal use of equipment and sample
transport network costs, such that higher test volumes in the periphery favor decentralized testing, whereas higher test volumes at the district
level favor centralized testing. Full assessment of all scenarios is available in Additional file 1: Section 1.5 and Figure S3
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median of $338,000 [IQR − $222,000; $889,000] per 20
million people.
The probability that decentralized Xpert would be
cost-effective depended strongly on decentralized testing
volume, degree of cost sharing for centralized specimen
transport, and the cost-effectiveness threshold. For ex-
ample, the probability that decentralized testing would
be cost-effective relative to centralized testing ranged
from 0.12 to 0.98 at a willingness to pay of $2000 per
DALY averted (Fig. 5). At very low peripheral testing
volumes (≤ 0.3 tests per day), decentralized Xpert was
unlikely to be cost-effective: even at a willingness to pay
of $6000 per DALY averted, the probability of cost-ef-
fectiveness remained below 0.8.
Sensitivity analyses
When comparing decentralized against centralized testing,
differences in outcome measures—epidemiological impact
of Xpert (Fig. 6a), costs (Fig. 6b), and DALYs (Fig. 6c)—
were generally robust to one-way variation in parameter
values. Incremental cost-effectiveness ratios (Fig. 6d)
likewise did not vary substantially in one-way sensitivity
analyses, with the uncertainty boundary remaining within
± 10% of the primary estimate. Increasing the amount of
Table 2 Incremental cost-effectiveness of decentralized versus centralized Xpert testing
Centralized Xpert
with 95% cost
sharing for specimen
transport
Centralized Xpert with no cost sharing
for specimen transport
Decentralized Xpert with
test volume at 3 per day
Decentralized Xpert with test
volume at 0.3 per day
Total costs (2015 US$, in
million)
$189 [$157–$222] $196 [$164–$230] $196 [$164–$230] $217 [$185–$253]
Total DALYs 740,124 [700,676–782,488] 730,923 [692,001–773,630]
Comparing centralized vs. decentralized Xpert
Centralized Xpert vs. Decentralized
Xpert
Difference in costs (2015 US$, in million) Difference in DALYs Cost per DALY averted (2015
US$)
95% cost sharing for
specimen transport
vs. Test volume at 3
per day
$7 [$6.6–$8] 9.26 [6231–12,112] $795 [$573–$1213]
No cost sharing for
specimen transport
vs. Test volume at 3
per day
− $0.33 [− $0.89 to $0.22] Dominated*
[dominated*–$29]
95% cost sharing for
specimen transport
vs. Test volume at
0.3 per day
$28 [$27–$30] $3161 [$2412–$4731]
No cost sharing for
specimen transport
vs. Test volume at
0.3 per day
$21 [$20–$22] $2339 [$1775–$3501]
A total of four cost sets were compared in the cost-effectiveness analysis. All values are expressed as median with interquartile ranges in brackets, cumulative and
discounted over a 10-year time horizon
*In the median simulations, decentralized Xpert was less costly and more effective than centralized testing
Fig. 4 Projected incremental epidemiological impact of decentralized versus centralized Xpert testing for tuberculosis (TB). Panels compare the
impact of Xpert implemented via a decentralized strategy compared to centralized testing, in terms of the cumulative number of DS-TB
infections averted (a), cumulative number of drug-resistant (DR) TB infections averted (b), and cumulative number of TB deaths averted (c). All
values are adjusted to a population size of 100,000. Shaded areas and arrows represent interquartile uncertainty ranges
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pre-treatment LTFU in the centralized scenario reduced
the epidemiological impact of Xpert and resulted in higher
costs and less favorable cost-effectiveness. For example,
when increasing the incremental probability of pre-treat-
ment LTFU with centralized (versus decentralized) testing
from 0 to 20%, the proportion of simulations favoring
decentralized Xpert (assuming moderate decentralized
volume, 95% centralized cost sharing, and a willingness-
to-pay threshold of $1000 per DALY averted) rose from 57
to 99%. Complete details of these analyses are given in
Additional file 1: Sections S3.1 and S3.2.
Performing SSM as a back-up test in addition to Xpert
(thereby allowing same-day diagnosis for all smear-posi-
tive patients) improved the epidemiological impact and
cost-effectiveness of centralized testing. For example, as-
suming moderate decentralized testing volume and no
cost-sharing for specimen transport, the probability that
decentralized testing would be cost-effective relative to
centralized testing was estimated as 0.61 (compared to
0.98 at baseline). For complete one-way sensitivity
analyses results, please see Additional file 1, Section
S3.3.
Discussion
This economic-epidemiological model of Xpert im-
plementation in India suggests that the economics of
decentralizing molecular testing for TB likely depend on
three important factors: the testing volume at decentra-
lized facilities and centralized facilities (i.e., how many
decentralized facilities are referring), the degree to which
costs of specimen transport can be shared with other
non-TB disease entities, and the level of pre-treatment
LTFU caused by the delays in centralized testing. Provided
that decentralized testing can be performed with equal
quality as centralized testing, the costs and LTFU incurred
by using a hub-and-spoke system are likely to justify the
increased costs of decentralized testing in most scenarios,
except in settings where testing volumes in the periphery
remain very low (mean < 1 test per day).
Our results may appear contrary to existing arguments
that point-of-care diagnosis is much more expensive
than centralized testing [28, 29]. Our findings reflect, in
part, the smaller capital outlay required for smaller
GeneXpert Omni and Edge devices: by enabling flexibi-
lity in procuring the number of modules based on test-
ing demands at peripheral centers at approximately one
fourth the price of a four-module device, these devices
enable smaller peripheral centers to perform point-of-
care testing without a substantive increase in unit costs.
However, in settings where the volume of decentralized
testing is very low (high costs associated with peripheral
testing infrastructure) and an established low-cost sam-
ple referral network exists, optimized hub-and-spoke
centralized testing is more likely to be cost-effective.
Fig. 5 Cost-effectiveness acceptability curves comparing decentralized versus centralized Xpert testing for tuberculosis (TB) in a representative
simulated Indian population. The x-axis shows the cost per disability-adjusted life year (DALY) averted via decentralized Xpert compared to
centralized testing, and the y-axis shows the proportion of stochastic simulations falling below each corresponding cost-effectiveness threshold.
Dotted vertical lines represent alternative thresholds for evaluating cost-effectiveness. For each threshold, the cost-effectiveness values are
computed for the four unit-cost comparisons when centralized specimen transport is utilized at no vs. 95% cost sharing and mean peripheral
testing volume ranges from 0.3 to 3 per day in the decentralized scenario
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Likewise, it may be financially infeasible to provide per-
ipheral Xpert in all settings (for example, India’s 2025
National Strategic Plan [14] aims to provide Xpert in
8335 MCs). Thus, our results advocate for prioritizing
decentralization of rapid TB CBNAAT in regions with
higher-than-average MC testing volumes and where
sample transport systems do not exist for TB or other
diseases while strengthening hub-and-spoke systems
(and continuation of smear microscopy) in regions with
lower testing volumes in the periphery.
In considering the implementation of molecular diag-
nostic testing for infectious diseases, it is important to
weigh cost-effectiveness alongside considerations of epi-
demiological impact and feasibility. Our results indicate
that the epidemiological impact of decentralized Xpert,
while modest, is sufficient to justify its incremental cost in
settings characterized by high pre-treatment LTFU,
provided that decentralized testing can be feasibly
implemented without a loss in quality. However, de-
centralized testing alone is unlikely to transform TB ep-
idemics in high-burden and heterogeneous settings like
India. Therefore, in places where patients are likely to
return for follow-up evaluation, parallel investments in
strengthening the centralized Xpert system is of equal
importance.
Furthermore, with a wide range of novel TB diagnostics
(designed for both more peripheral or more centralized
placement) [30] approaching market entry, placement
strategies for these new technologies will become an
important policy debate as countries push to increase the
coverage of quality TB diagnosis and care. Our results
illustrate that, for technologies optimized for higher level
laboratories (e.g., whole-genome sequencing), ability to
ensure high testing volumes at the central level and
to share health system infrastructure (e.g., specimen
transport network) will be important determinants of
cost utility. For diagnostics designed for more peri-
pheral placement (e.g., Xpert Edge and Omni, Molbio
Truenat MTB), important cost-effectiveness consider-
ations will also include the ability to achieve similar
diagnostic performance with simplified logistical infra-
structure. As countries plan investments to strengthen
the TB care cascade, cost and impact of technologies
optimized for different placement strategies must be
carefully evaluated against TB control priorities, budget,
and current health systems constraints.
Fig. 6 One-way sensitivity analysis to the value of selected model parameters. Panels show the sensitivity of epidemiological outputs (reduction
in DS-TB incidence in panel a), costing outcomes (difference in costs in panel b), and DALYs averted (in panel c) comparing decentralized to
centralized TB testing, and the proportion of simulations that remain cost-effective at a threshold of $1000 (panel d) under one-way variation in
the value of selected model parameters. Each parameter value is followed by an up/down arrow, denoting an increase (↑) or decrease (↓) in the
input parameter value as listed in Table 1. Each scenario is simulated starting in the year 2018 and is followed to the year 2028 under centralized
and decentralized Xpert placement. The bars and arrows represent the median and interquartile ranges across 1000 simulations. The red mark
and dashed line represent the baseline scenario with no parameter variation. The results are summarized by showing the five parameters for
which variation resulted in the largest variations from the baseline scenario (increasing in impact from top to bottom)
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As with any modeling exercise, our study has certain
limitations. We adopted a number of simplifying
assumptions, including homogeneous mixing, represen-
tation of India’s TB diagnostic landscape as having only
three tiers (informal, formal private, and public), and
representation of the diagnostic process as occurring
within a discrete number of specific encounters. To the
extent that these simplifications depart from the com-
plex reality of TB transmission and diagnosis in the
Indian healthcare system, we may over- or underesti-
mate the epidemiological impact and cost-effectiveness
of decentralized testing. The most important assump-
tions in this model are the degree to which decentralized
Xpert testing will reduce those who will be permanently
lost in the TB care cascade (pre-treatment LTFU, relative
to centralized testing) and the degree to which patients
will return for follow-up evaluation. Given the complex-
ity of the TB care cascade and patient care-seeking
behaviors [31], implementation of decentralized testing
alone may not achieve substantive reductions in LTFU
[32]. We also did not consider costs of implementing
programmatic interventions that may be necessary to
translate peripheral testing into reductions in LTFU;
where such interventions are required (or where
LTFU is already low, even with centralized testing),
the cost-effectiveness of decentralized Xpert may be
much less favorable than projected here. Nevertheless,
we estimated that decentralized testing could be im-
plemented at a lower unit cost than centralized test-
ing in many situations—and to the extent that this
can be accomplished (without a loss in quality),
decentralized testing is likely to be preferred. Finally,
we assumed, for the purpose of comparison, a setting
in which Xpert was scaled up as a first-line test for
TB among all adults with symptoms; cost-effective-
ness of Xpert overall (and of decentralized Xpert rela-
tive to centralized Xpert) may be improved by
adoption of other algorithms, such as focusing on
high-priority populations [33].
Conclusions
We have used a combined epidemic-economic model
to illustrate that decentralized Xpert testing for TB is
likely to be a cost-effective strategy in settings charac-
terized by high LTFU, moderate-to-high peripheral
testing volumes, and inability to share costs of speci-
men transport with other disease entities. Our find-
ings reflect the fact that single-module devices enable
testing to be performed at lower volumes without
considerable increases in per-test costs. Decisions to
implement decentralized testing should not be based
solely on cost-effectiveness but must also consider
budget constraints, feasibility of implementation with-
out a loss in quality, and the degree to which such
testing is likely to reduce LTFU in actual practice.
Assuming these factors can be addressed, this model-
ing analysis supports the scale-up of decentralized
Xpert testing for TB as a mechanism to achieve uni-
versal access to high-quality TB diagnosis in India
and other similar settings.
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